Selah Genomics, BD, Others Partner to Use NGS in Colon Cancer Care | GenomeWeb

NEW YORK (GenomeWeb) – Selah Genomics, a subsidiary of EKF Diagnostics, today announced a collaboration with Greenville Health System, DecisionQ, and Becton Dickinson to integrate next-generation sequencing into the care of colon cancer patients.

As part of the 18-month partnership, Selah Genomics will use its PrecisionPath NGS technology to profile tumor samples provided by the Institute for Translational Oncology Research (ITOR), part of GHS's Cancer Institute. The samples, from colon cancer patients, will be provided with full clinical annotation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Sponsored by

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.